UBS Asset Management granted Private Fund Management license in China
UBS Asset Management today announced that its wholly foreign-owned enterprise (WFOE), UBS Asset Management (Shanghai) Limited, has been granted a Private Fund Management (PFM) license from the Asset Management Association of China (AMAC). The license allows the WFOE to offer onshore fixed income, equity, and multi-asset private funds to both institutional and high net worth investors in China.
"China is a key growth market for UBS Asset Management. Our goal is to be a leading asset manager in China for both onshore and offshore investors and a strong partner to Chinese clients investing overseas," said Ulrich Koerner, President of UBS Asset Management.
"UBS Asset Management is the first international manager with a QDLP quota to receive a PFM license in China’s onshore market. Securing the license expands the breadth and depth of our domestic offering, complements our offshore capabilities and, importantly, demonstrates our continued support of China in its efforts to open its capital markets to the world," said Rene Buehlmann, Group Managing Director, Head Asia Pacific at UBS Asset Management.
"UBS Asset Management has been serving China investors since the 1990s. With the addition of the PFM license, augmented by our other platforms in China, we can provide a broad range of services to onshore and global clients. It also allows us to work more closely with subsidiaries of global firms in China to meet their domestic investment needs," he added.
In 2005, UBS AM entered into a joint venture with the State Development & Investment Corporation (SDIC), to form UBS SDIC Fund Management Co. Ltd, which offers onshore mutual funds. In addition, in 2011, UBS Asset Management (China) Limited was established as WFOE in Beijing to provide investment management and advisory services for alternative investment.
"With the continued liberalisation of China’s economy, domestic investors can be expected to seek to diversify their investments across a broad and expanding range of traditional and alternative asset classes and geographies. UBS is well positioned to help them build portfolios which not only have the potential to generate reasonable returns but also diversify downside risk," explained Aries Tung, Managing Director, Head of Strategy and Business Development, China, at UBS Asset Management.
"We are committed to establishing a market-leading private fund platform in China supported by local infrastructure, best-in-class client services, and rigorous risk management," he added.
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. The operational structure of the Group is comprised of our Corporate Center and five business divisions: Wealth Management, Wealth Management Americas, Personal & Corporate Banking, Asset Management and the Investment Bank. UBS's strategy builds on the strengths of all of its businesses and focuses its efforts on areas in which it excels, while seeking to capitalize on the compelling growth prospects in the businesses and regions in which it operates, in order to generate attractive and sustainable returns for its shareholders. All of its businesses are capital-efficient and benefit from a strong competitive position in their targeted markets.
UBS is present in all major financial centers worldwide. It has offices in 54 countries, with about 34% of its employees working in the Americas, 35% in Switzerland, 18% in the rest of Europe, the Middle East and Africa and 13% in Asia Pacific. UBS Group AG employs approximately 60,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).
This document and its contents have not been reviewed by, delivered to or registered with any regulatory or other relevant authority in any jurisdiction. This document is for informational purposes and should not be construed as an offer or invitation to the public, direct or indirect, to buy or sell securities. This document is intended for limited distribution and only to the extent permitted under applicable laws in any jurisdiction. No representations are made with respect to the eligibility of any recipients of this document to acquire interests in securities under the laws of any jurisdiction.
Using, copying, redistributing or republishing any part of this document without prior written permission from UBS Asset Management is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this document is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this document are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS Asset Management’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.
You are advised to exercise caution in relation to this document. The information in this document does not constitute advice and does not take into consideration your investment objectives, legal, financial or tax situation or particular needs in any other respect. Investors should be aware that past performance of investment is not necessarily indicative of future performance. Potential for profit is accompanied by possibility of loss. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.
Source for all data and charts (if not indicated otherwise): UBS Asset Management.
© UBS 2017. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.
Mark Panday (Hong Kong), email@example.com, T: +852 2971 8221
Joanna Sin (Hong Kong), firstname.lastname@example.org, T: +852 2971 7950
Krystal Miller (London), email@example.com, T: +44 207 901 5537
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
GA-ASI to Fly First Trans-Atlantic Flight of a MALE RPA25.6.2018 19:55 | Tiedote
On July 10-11, General Atomics Aeronautical Systems, Inc. (GA-ASI) plans to make the first-ever trans-Atlantic flight of a Medium-altitude, Long-endurance (MALE) Remotely Piloted Aircraft (RPA). GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static display July 13-15 for the Royal International Air Tattoo (RIAT) airshow being held at RAF Fairford. The flight and display will commemorate the RAF’s centenary celebration (RAF100). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005946/en/ GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static displa
Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30 | Tiedote
www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re
The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00 | Tiedote
The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and
Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22 | Tiedote
Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07 | Tiedote
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type
European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection25.6.2018 15:03 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIC/FTC/TAF combines the potency of the novel integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF), a guidelines-recommended dual nucleoside reverse transcriptase inhibitor (NRTI) backbone. Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years. In Europe, BIC/FTC/TAF is indicated as a complete regimen for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or tenofovir. No dosage adjustment of BIC/FTC/TAF is required in patien
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme